Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2020 Dec 7

PMID 33283136

Citations 3

Authors

Anya Levinson

Alex G Lee

Henry J Martell

Marcus R Breese

Charles Zaloudek

Jessica Van Ziffle

Benjamin Laguna

Stanley G Leung

M Dwight Chen

Lee-May Chen

Jacob Pfeil

Nicholas R Ladwig

Avanthi Tayi Shah

Inge Behroozfard

Arjun Arkal Rao

Sofie R Salama

E Alejandro Sweet-Cordero

Elliot Stieglitz

Affiliations

Soon will be listed here.

Citing Articles

Clear Cell Carcinoma of the Uterine Cervix in a 14-Year-Old Girl: A Case Report.

Motomura M, Hachisuga K, Yagi H, Yahata H, Kato K Cureus. 2025; 17(1):e77060.

PMID: 39917107 PMC: 11800169. DOI: 10.7759/cureus.77060.

Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis.

McGuinness C, Black M, Dunbier A Cancer Med. 2023; 12(23):21545-21560.

PMID: 37974533 PMC: 10726921. DOI: 10.1002/cam4.6711.

Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.

Bulutay P, Eren O, Ozen O, Haberal A, Kapucuoglu N Turk J Obstet Gynecol. 2023; 20(3):164-173.

PMID: 37667475 PMC: 10478723. DOI: 10.4274/tjod.galenos.2023.62819.

Primary Clear Cell Adenocarcinoma of the Uterine Cervix in a 14-Year-Old Virgin Girl: Case Report.

Bujor I, Lozneanu L, Ursache A, Cristofor A, Scurtu A, Plamadeala P Int J Environ Res Public Health. 2022; 19(24).

PMID: 36554533 PMC: 9779421. DOI: 10.3390/ijerph192416652.

References

Thomas M, Wright J, Leiser A, Chi D, Mutch D, Podratz K . Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. 2008; 109(3):335-9. PMC: 3667392. DOI: 10.1016/j.ygyno.2008.02.007. View

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

Glasspool R, McNeish I . Clear cell carcinoma of ovary and uterus. Curr Oncol Rep. 2013; 15(6):566-72. DOI: 10.1007/s11912-013-0346-0. View

Boyd J, Takahashi H, Waggoner S, Jones L, Hajek R, Wharton J . Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer. 1996; 77(3):507-13. DOI: 10.1002/(SICI)1097-0142(19960201)77:3<507::AID-CNCR12>3.0.CO;2-8. View

Reich O, Tamussino K, Lahousen M, Pickel H, Haas J, Winter R . Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol. Gynecol Oncol. 2000; 76(3):331-5. DOI: 10.1006/gyno.1999.5700. View

Cho H, Kim J, Chung H, Perry C, Lee H, Kim J . Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol. 2013; 44(7):1365-74. DOI: 10.1016/j.humpath.2012.11.007. View

Chen P, Roh W, Reuben A, Cooper Z, Spencer C, Prieto P . Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016; 6(8):827-37. PMC: 5082984. DOI: 10.1158/2159-8290.CD-15-1545. View

Tewari K, Sill M, Long 3rd H, Penson R, Huang H, Ramondetta L . Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734-43. PMC: 4010094. DOI: 10.1056/NEJMoa1309748. View

Alexandrov L, Kim J, Haradhvala N, Huang M, Ng A, Wu Y . The repertoire of mutational signatures in human cancer. Nature. 2020; 578(7793):94-101. PMC: 7054213. DOI: 10.1038/s41586-020-1943-3. View

10.

Luksza M, Riaz N, Makarov V, Balachandran V, Hellmann M, Solovyov A . A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017; 551(7681):517-520. PMC: 6137806. DOI: 10.1038/nature24473. View

11.

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading J . Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017; 18(8):1009-1021. DOI: 10.1016/S1470-2045(17)30516-8. View

12.

Wang S, Jia M, He Z, Liu X . APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018; 37(29):3924-3936. PMC: 6053356. DOI: 10.1038/s41388-018-0245-9. View

13.

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

14.

Kline C, Joseph N, Grenert J, Van Ziffle J, Talevich E, Onodera C . Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017; 19(5):699-709. PMC: 5464451. DOI: 10.1093/neuonc/now254. View

15.

Rao A, Madejska A, Pfeil J, Paten B, Salama S, Haussler D . ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy. Front Immunol. 2020; 11:483296. PMC: 7683782. DOI: 10.3389/fimmu.2020.483296. View

16.

Chen Z, Wen W, Bao J, Kuhs K, Cai Q, Long J . Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types. BMC Med Genomics. 2019; 12(1):131. PMC: 6751822. DOI: 10.1186/s12920-019-0579-3. View

17.

Jager M, Blokzijl F, Kuijk E, Bertl J, Vougioukalaki M, Janssen R . Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer. Genome Res. 2019; 29(7):1067-1077. PMC: 6633256. DOI: 10.1101/gr.246223.118. View

18.

Ma X, Liu Y, Liu Y, Alexandrov L, Edmonson M, Gawad C . Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018; 555(7696):371-376. PMC: 5854542. DOI: 10.1038/nature25795. View

19.

Toor J, Rao A, McShan A, Yarmarkovich M, Nerli S, Yamaguchi K . A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations. Front Immunol. 2018; 9:99. PMC: 5797543. DOI: 10.3389/fimmu.2018.00099. View

20.

Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C . Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14):1345-1356. PMC: 5706778. DOI: 10.1056/NEJMoa1709684. View